Situation Analysis

• The client is a European biopharma company poised to advance its clinical programs for the treatment of rare central nervous system (CNS) diseases which have limited or no viable treatment options

• The company was looking to leverage U.S. capital markets, but it was faced with limited visibility or interest from U.S. investor community

Solution

• LHS Reach™ targeting strategy to establish relationships with key U.S. institutional investors, research analysts, and bankers

• Reposition and brand the client as a CNS-focused, orphan disease company, and completely overhaul its corporate presentation

• Educated stakeholders on the company's vision, mission and value proposition in preparation for its future activities in the U.S. market

• Identify the right opportunities for management to present the corporate story to key U.S. stakeholders

Results​​

• Enabled the client to complete a $5.4 million private placement with a leading U. S. biotechnology and healthcare specialist fund in November 2015

• Coordinated more than 30 one-on-one meetings with high quality investors and executed on two banking non-deal roadshows with an additional 20 meetings

• Increased awareness of the corporate profile and understanding of the company’s value proposition among the key stakeholders